US 11802158
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
granted A61KA61K39/395A61K47/6831
Quick answer
US patent 11802158 (Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same) held by CytomX Therapeutics, Inc. expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K39/395, A61K47/6831, A61K47/6845, A61K47/6849